Marc S. Sabatine

4 ta ish

Harvard University

1. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: <i>lipid modification to reduce cardiovascular risk</i>

   François Mach, Colin Baigent, Alberico L. Catapano +87

   MaqolaOAOchiq kirish20198 iqtibos

   ABIABI:AkademIndex/2026.other.057803

2. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction

   John J.V. McMurray, Scott D. Solomon, Silvio E. Inzucchi +35

   Maqola20196 iqtibos

   ABIABI:AkademIndex/2026.other.282514

3. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes

   Stephen D. Wiviott, Itamar Raz, Marc P. Bonaca +17

   Maqola20183 iqtibos

   ABIABI:AkademIndex/2026.other.282509

4. Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions

   Michael G. Silverman, Brian A. Ference, Kyungah Im +5

   Sharh maqolaOAOchiq kirish20162 iqtibos

   ABIABI:AkademIndex/2026.other.057707